Dan Janiak, PhD, serves as Chief Business Officer of OncoC4. He brings more than 15 years of experience building, financing, and scaling biotechnology companies across oncology, neurology, and rare diseases, with expertise in corporate strategy, business development, venture investing, and company formation.

Most recently, Dan served as Executive Director of Business Development at AstraZeneca, where he led oncology platform transactions involving artificial intelligence, machine learning, and enabling technologies. Previously, he was President and Chief Operating Officer of Trotana Therapeutics and the first employee of Taysha Gene Therapies, where he served as Senior Vice President of Corporate Strategy and Business Development and helped build the company from inception.

Earlier in his career, Dan held strategy and corporate development roles at VelosBio and AveXis. He began his career in venture investing and company formation at Mercury Fund and In-Q-Tel, managing investments across therapeutics and medical technologies and advising emerging biopharmaceutical companies.

Dan is a Kauffman Fellow and earned his PhD from the University of Maryland, College Park, where he held the Fischell Fellowship in Biomedical Engineering.